Fate Therapeutics Gets FDA Clearance for FT839 Autoimmune CAR-T Thera…

Fate Therapeutics has received FDA clearance for FT839, an allogeneic CAR-T therapy targeting both CD19 and CD38 to address multi-system autoimmune disorders where single-antigen approaches fail. The platform combines dual chimeric antigen receptors on a single iPSC-derived cell product, projected at $20,000–$40,000 per patient versus $100,000–$150,000 for autologous CAR-T, and is designed to eliminate conditioning chemotherapy in Phase 1/2 trials beginning H2 2026. If you're building conditioning-free CAR-T logistics, patient access infrastructure, or manufacturing for iPSC-derived cell products, Fate just proved the economics work at one-fifth the price of autologous. The market is moving from oncology centres to rheumatology clinics—that's your customer base.